On Heels of Remsima Launch, Celltrion Gears Up For Herceptin Biosimilar Approval In Korea
This article was originally published in PharmAsia News
Executive Summary
Following the start of sales of Remsima, a biosimilar of J&J’s Remicade, Celltrion is moving to begin selling its Herceptin biosimilar in Korea this year. It will be Celltron’s second biosimilar on the market.